Pharming Group N.V.

ENXTAM:PHARM Stock Report

Market Cap: €503.4m

Pharming Group Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Fabrice Chouraqui

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenureno data
CEO ownershipn/a
Management average tenure3.8yrs
Board average tenure3.8yrs

Recent management updates

Recent updates

Pharming Group N.V. (AMS:PHARM) Held Back By Insufficient Growth Even After Shares Climb 26%

Dec 21
Pharming Group N.V. (AMS:PHARM) Held Back By Insufficient Growth Even After Shares Climb 26%

Revenues Working Against Pharming Group N.V.'s (AMS:PHARM) Share Price

Feb 14
Revenues Working Against Pharming Group N.V.'s (AMS:PHARM) Share Price

Health Check: How Prudently Does Pharming Group (AMS:PHARM) Use Debt?

Nov 11
Health Check: How Prudently Does Pharming Group (AMS:PHARM) Use Debt?

Pharming Group N.V. (AMS:PHARM) Shares Could Be 49% Below Their Intrinsic Value Estimate

Aug 23
Pharming Group N.V. (AMS:PHARM) Shares Could Be 49% Below Their Intrinsic Value Estimate

Health Check: How Prudently Does Pharming Group (AMS:PHARM) Use Debt?

Jun 20
Health Check: How Prudently Does Pharming Group (AMS:PHARM) Use Debt?

Is Pharming Group (AMS:PHARM) Using Too Much Debt?

Mar 16
Is Pharming Group (AMS:PHARM) Using Too Much Debt?

Pharming Group N.V.'s (AMS:PHARM) Intrinsic Value Is Potentially 41% Above Its Share Price

Feb 17
Pharming Group N.V.'s (AMS:PHARM) Intrinsic Value Is Potentially 41% Above Its Share Price

We Think Pharming Group (AMS:PHARM) Can Manage Its Debt With Ease

Dec 08
We Think Pharming Group (AMS:PHARM) Can Manage Its Debt With Ease

Is Pharming Group (AMS:PHARM) Using Too Much Debt?

Aug 05
Is Pharming Group (AMS:PHARM) Using Too Much Debt?

Pharming Group N.V. Just Missed EPS By 56%: Here's What Analysts Think Will Happen Next

Mar 21
Pharming Group N.V. Just Missed EPS By 56%: Here's What Analysts Think Will Happen Next

These Analysts Think Pharming Group N.V.'s (AMS:PHARM) Sales Are Under Threat

Mar 19
These Analysts Think Pharming Group N.V.'s (AMS:PHARM) Sales Are Under Threat

Is Pharming Group (AMS:PHARM) Using Too Much Debt?

Feb 20
Is Pharming Group (AMS:PHARM) Using Too Much Debt?

Pharming Group N.V.'s (AMS:PHARM) Intrinsic Value Is Potentially 40% Above Its Share Price

Oct 29
Pharming Group N.V.'s (AMS:PHARM) Intrinsic Value Is Potentially 40% Above Its Share Price

CEO

Fabrice Chouraqui

no data

Tenure

Mr. Fabrice Chouraqui, Ph D., has been Chief Executive Officer and Executive Director of Pharming Group N.V. since March 4, 2025. He has been the Chief Executive Officer-Partner of Flagship Pioneering and...


Leadership Team

NamePositionTenureCompensationOwnership
Sijmen de Vries
Advisorno dataUS$2.81m2.13%
€ 10.7m
Fabrice Chouraqui
CEO & Executive Directorno datano datano data
Jeroen Wakkerman
Chief Financial Officer4.3yrsno data0.063%
€ 318.8k
Mireille Sanders
Chief Operations Officer5.6yrsno data0.12%
€ 591.3k
Susanne Embleton
Investor Relations Managerno datano datano data
Ruud Van Outersterp
Chief Ethics & Compliance Officer3.8yrsno data0.024%
€ 122.2k
Ines Bernal
Chief People Officerless than a yearno datano data
Anurag Relan
Chief Medical Officer3.8yrsno data0.027%
€ 136.3k
Stephen Toor
Chief Commercial Officer & GM Americas8.2yrsno data0.028%
€ 138.9k
Alexander Breidenbach
Chief Business Officer1.5yrsno data0.0096%
€ 48.4k
Bruno M. Giannetti
Consultant3.8yrsno datano data

3.8yrs

Average Tenure

58yo

Average Age

Experienced Management: PHARM's management team is considered experienced (3.8 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Fabrice Chouraqui
CEO & Executive Directorno datano datano data
Leonard Kruimer
Independent Non-Executive Director3.8yrsUS$90.00k0.018%
€ 89.7k
Mark Pykett
Independent Non-Executive Director4.3yrsUS$87.00k0.021%
€ 108.1k
Deborah Jorn
Independent Non-Executive Vice-Chairperson5.8yrsUS$87.00k0.024%
€ 119.6k
Steven Baert
Independent Non-Executive Director3.8yrsUS$90.00k0.018%
€ 89.7k
Barbara Yanni
Independent Non-Executive Director4.3yrsUS$94.00k0.021%
€ 108.1k
Richard Peters
Non-Executive Chairman of Board1.5yrsUS$46.00k0.0092%
€ 46.5k
Jabine van der Meijs
Independent Non-Executive Director3.8yrsUS$94.00k0.018%
€ 89.7k

3.8yrs

Average Tenure

62yo

Average Age

Experienced Board: PHARM's board of directors are considered experienced (3.8 years average tenure).


Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/03/11 19:11
End of Day Share Price 2025/03/11 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Pharming Group N.V. is covered by 14 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
John SavinEdison Investment Research
Simon ScholesFirst Berlin Equity Research GmbH
Joseph PantginisH.C. Wainwright & Co.